Hot Selling Dulaglutide Best price Pure 99% Powder CAS 923950-08-7
2 Inquiries
923950-08-7
Pharmaceutical Grade
99%
ShangHai
Eternal Wealth
1g,10g,50g or according to customer's detail requirement.
2025-05-10
Semaglutide,Tirzepatide,Retatrutide,Pharmaceutical Peptide,Cosmetic peptide,Custom peptides
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Dulaglutide is a long-acting GLP-1 receptor agonist and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Dulaglutide is widely used in API research, pharmaceutical development, analytical testing, and manufacturing processes. It is available in high-purity grades with specifications based on pharmaceutical quality requirements.
Basic Info-
Product Name:
Dulaglutide
Other Name:Dulaglutide - solution in PBS;Dulaglutide USP/EP/BP;Dulaglutide;Research Grade Dulaglutide(DHE40129);Research Grade Dulaglutide;Dulaglutide (Trulicity;LY2189265);Dulaglutide(sodium salt)
CAS No.:923950-08-7
Molecular Weight:0
EC Number:200-001-8
Color/Form:Colorless to light yellow
Categories:
Research-
Class:
GLP-1 receptor agonist (GLP-1 analog fused to human IgG4-Fc, long-acting)
Status:FDA-approved (Trulicity 2014)
Mechanism:A long-acting GLP-1 receptor agonist consisting of a modified human GLP-1 molecule (7-37) covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The Fc fusion extends the half-life to ~5 days, allowing once-weekly dosing. Activates GLP-1R to enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying.
Activity note:Dulaglutide is a dual-agonist with GLP-1R activation. The exact EC50 is proprietary; functional potency is comparable to other long-acting GLP-1R agonists.
Source:DrugBank: DB09095; PubChem CID 16135271.
Clinical Development:FDA:Trulicity (approved 2014-09-18)
References-
DrugBank:PubChem:Disclaimer:
Dulaglutide is FDA-approved as a prescription medicine (Trulicity) for type 2 diabetes. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Semaglutide,Tirzepatide,Retatrutide,Pharmaceutical Peptide,Cosmetic peptide,Custom peptides
-
Location:
Room 204, Building 2, No. 398 Jinhuan Road, Jinshan District, Shanghai, China
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2014
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
Turkey
Dulaglutide
1 G Jun 5, 2026 
United States
dulaglutide
4 Mar 11, 2026 Post an enquiry for this product
